Interestingly, this IHC profile with a good-prognosis value mirrored the molecular profile (MARCKS-downregulated/PTEN-upregulated) of MPS-treated IBC cell lines, indirectly the potential therapeutic benefit of MARCKS inhibition. This evidence concerns the gene MARCKS and mucopolysaccharidosis.